Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

MacKenzie Montag

Nurse Practitioner, Pediatrics Lone Tree, CO Nurse Practitioner

NPI 1609439371 CMS profile 10697315

10465 Park Meadows Dr Ste 201, Lone Tree, CO 80124

Open in the dashboard

General payments

$2,267

99 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, MacKenzie Montag of Lone Tree, CO is reported in the CMS Open Payments database as having received $2,267 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $590 20
2024 General $444 20
2023 General $449 22
2022 General $525 24
2021 General $259 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • MacKenzie Montag
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to MacKenzie Montag were reported at $590. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year MacKenzie Montag Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $259 $60 $23–$142 $132
2022 $525 $72 $27–$161 $149
2023 $449 $89 $35–$185 $160
2024 $444 $93 $34–$199 $164
2025 $590 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $355 17 payments
  2. Regeneron Healthcare Solutions, Inc. $354 14 payments
  3. AbbVie, Inc. $346 16 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $247 11 payments
  5. QOL Medical, LLC $210 11 payments
  6. Nestle HealthCare Nutrition Inc. $200 11 payments
  7. Janssen Biotech, Inc. $198 3 payments
  8. Pharming Healthcare, Inc. $81 3 payments
  9. Mirum Pharmaceuticals, Inc. $66 3 payments
  10. Ipsen Biopharmaceuticals, Inc $53 2 payments
  11. Other $158 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,220 96 payments
  2. Education $47 3 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $339 16 payments
  2. DUPIXENT Inflammation And Immunology $297 12 payments
  3. ZENPEP $233 13 payments
  4. CREON $208 9 payments
  5. LINZESS $178 8 payments
  6. TREMFYA $173 2 payments
  7. GATTEX $166 6 payments
  8. RUCONEST $81 3 payments
  9. Sucraid Therapy For Csid $77 4 payments
  10. Sucraid Therapy For Csid $73 4 payments
  11. Other $454 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record